https://www.eurekale...h-ads102918.php
NEW YORK, NY (November 1, 2018) Researchers from the Icahn School of Medicine at Mount Sinai found that patients with Major Depressive Disorder (MDD) exhibited a significant reduction of depressive symptoms after being treated with ezogabine, an FDA approved drug used to treat seizures.
After treatment, patients showed a 45 percent reduction in depression, a significant reduction in anhedonia, the inability to feel pleasure; and a significant increase in resilience.
The cruel irony is that it was discontinued and only available if you enter a randomized double-blind placebo trial. Potassium channel openers seem very promising to treat anhedonia, but I don't know of any drugs that share a similar mechanism of action with a low side-effect profile.
Edited by justabody, 29 November 2018 - 06:36 AM.